Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.
William E RussellBrian N BundyMark S AndersonLaura A CooneyStephen E GitelmanRobin S GolandPeter A GottliebCarla J GreenbaumMichael J HallerJeffrey P KrischerIngrid M LibmanCarla J GreenbaumSarah Alice LongSandra M LordDaniel J MooreWayne V MooreAntoinette M MoranAndrew B MuirPhilip RaskinJay S SkylerJohn M WentworthDiane K WherrettDarrell M WilsonAnette-Gabriele ZieglerKevan C Heroldnull nullPublished in: Diabetes care (2023)
Although abatacept treatment for 1 year did not significantly delay progression to glucose intolerance in at-risk individuals, it impacted immune cell subsets and preserved insulin secretion, suggesting that costimulation blockade may modify progression of type 1 diabetes.